We create innovative treatments for nervous system damage due to injury or disease.
Number of people in the US living with SCI, MS and Alzheimer’s
NervGen’s Mission
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
NervGen Pharma
NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company creating innovative treatments that enable the nervous system to repair itself following damage. NervGen’s lead drug candidate, NVG-291 is currently in a Phase 1 clinical trial. The company’s initial target indications are spinal cord injury, Alzheimer’s disease and multiple sclerosis.
View our Corporate Presentation
Our Technology
The nervous system is a complex network of nerves and cells that carries messages to and from the brain and spinal cord to various parts of the body to take in sensory information, process information and control movement. Damage to the nervous system can result in disruption to any, or all, of these functions. For a long time, everyone believed the nervous system could not repair itself, but that’s not the case.
Our Team
Bill Radvak
Interim Chief Executive Officer
Adam Rogers
Interim President
Dan Mikol
Chief Medical Officer
Bill Adams
Chief Financial Officer
Nana Collett
Vice President, Program Management
Matvey Lukashev
Vice President, Research and Preclinical Development
Stay Connected
Subscribe to our mailing list to stay up to date
The Latest
News Release
February 14, 2023
NervGen announced that all subjects (male, premenopausal and post-menopausal females) in the Phase 1 clinical trial of the Company’s proprietary lead compound, NVG-291, have completed dosing.
Article
July 28, 2022
Unlike existing treatments that focus on rehabilitation or reducing the risk of an additional stroke, the experimental drug targets the "stickiness" that can prevent injured brain tissue from functioning as it should
MEDIA
February 15, 2023
NervGen Pharma Corporate Update with Bill Radvak and Torrey Hills Capital. Click below to watch.